Prospective Surveillance Drug and HDS-Induced Liver Injury

Information

  • Research Project
  • 9325501
  • ApplicationId
    9325501
  • Core Project Number
    U01DK083027
  • Full Project Number
    5U01DK083027-11
  • Serial Number
    083027
  • FOA Number
    RFA-DK-13-003
  • Sub Project Id
  • Project Start Date
    9/30/2008 - 16 years ago
  • Project End Date
    6/30/2018 - 6 years ago
  • Program Officer Name
    SERRANO, JOSE
  • Budget Start Date
    7/1/2017 - 7 years ago
  • Budget End Date
    6/30/2018 - 6 years ago
  • Fiscal Year
    2017
  • Support Year
    11
  • Suffix
  • Award Notice Date
    8/24/2017 - 7 years ago

Prospective Surveillance Drug and HDS-Induced Liver Injury

DESCRIPTION (provided by applicant): The Drug Induced Liver Injury Network (DILIN), funded by the National Institutes of Health, represents a critical strategy to mitigate the adverse consequences of DILI. Already, this extensive network of centers around the U.S. has cultivated an impressive repertoire of case based clinical information and samples which has given important insights into DILI in the U.S. Some of the salient findings that have shaped our understanding of DILI and impact future research plans include the observation that antibiotics are the most common class of agents implicated in DILI, followed by Herbal and Dietary Supplements (HDS). The specific aims of this o Application are as follows: 1) To accrue early DILI cases, and collect serum, tissue, and clinical information on those patients meeting entry criteria through three mechanisms: Gastroenterologist- based; electronic health record (EHR); and population-based surveillance; 2) To continue to administer the DILIN Repository for Herbal and Dietary Supplements (HDS) and facilitate collaborative descriptive and product analysis and genetics research to identify injurious agents and host factors responsible for HDS induced liver injury (HILI); 3) To lead DILIN's effort in the causality assessment process for HILI, including it validation, and contribute to its incorporation into a computer-based instrument that is practical for clinicians and applicable for assessment of injury due to both drugs and HDS; 4) To contribute to the expansion of the Herbal and Dietary Supplement component of LiverTox and facilitate the use of LiverTox as a mechanism for DILI reporting by the medical community at large. To accomplish these aims, key collaborations have been built. Informatics specialists will assist in the design, implementation, validation, and refinement of an electronic health record algorithm. Collaborations have also been built with geneticists and the FDA toxicology group to explore the mechanisms for idiosyncratic liver injury from HDS, as well as to identify the agents responsible for injury. Our research will further refine causality assessment, particularly as it pertains to HILI. Finally, the proposed work will expand the functionality of LiverTox, both as a resource for the clinician and clinical scientist, as well as the individual seeking to report a cae of DILI or HILI.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    U01
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
    295494
  • Indirect Cost Amount
    139345
  • Total Cost
    434839
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    999
  • Ed Inst. Type
  • Funding ICs
    NIDDK:434839\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZDK1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ALBERT EINSTEIN HEALTHCARE NETWORK
  • Organization Department
  • Organization DUNS
    148406911
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191413098
  • Organization District
    UNITED STATES